Putting it All Together: Tools for Documenting Chronic GVHD Response Assessment Sandra A. Mitchell, CRNP, M.Sc.N., AOCN National Institutes of Health Bethesda,

Slides:



Advertisements
Similar presentations
Emergency Care Part 1: Managing Diabetic Ketoacidosis (DKA)
Advertisements

Neurocognitive Testing in the Metabolic Clinic …moving from concept to practice
Rare Film Guide Slide Set. Clinical Trial Design for Pirfenidone Study Purpose of Study: To see if the use of pirfenidone decreases the loss of lung function.
Great Ormond Street Hospital for Children NHS Trust The School of Pharmacy UCL INSTITUTE OF CHILD HEALTH Centre for Paediatric Pharmacy Research Drug Development.
Overview of Chronic GVHD Response Assessment
Chronic GVHD Symptoms Sandra A. Mitchell, CRNP, M.Sc.N., AOCN
Copyright Alcohol Medical Scholars Program A Clinical Guide To Assessing Alcohol Use And Problems Andrea DiMartini M.D. University of Pittsburgh.
Self-Report of Functional Status and Quality of Life: Children Susan K. Parsons, MD, MRP Director, Center on Child and Family Outcomes, ICRHPS Tufts-NEMC.
Ocular Manifestations Stella K. Kim, M.D. MD Anderson Cancer Center Houston, TX Michael R. Robinson, M.D. National Eye Institute National Institutes of.
ADHD Assessment and Treatment in Primary Care Jodi Polaha, Ph.D. Assistant Professor, Pediatrics Munroe-Meyer Institute University of Nebraska Medical.
Laboratory and Diagnostic Studies Sandra A. Mitchell, CRNP, M.Sc.N., AOCN National Institutes of Health Bethesda, MD.
Intravenous Iron Supplementation and Chronic Kidney Disease Chloe Bierbower December 2, 2013.
Objective Measures of Physical Performance in Chronic GVHD: Pediatrics David A. Jacobsohn, M.D. Kimberly E. Thormann, M.A., CPNP Children’s Memorial Hospital.
Self-Report Measures of Functional Status and Quality of Life: Adults Sandra A. Mitchell, CRNP, M.Sc.N., AOCN National Institutes of Health Bethesda, MD.
ADHD Assessment and Treatment in Primary Care BHC Outreach Meeting December 10, 2004.
The PHQ9 Screening Tool for Depression. The PHQ9 Nine item depression module derived from the full Patient Health Questionnaire (PHQ) Depression screening.
LEUKEMIA. What Is It? Leukemia is a type of cancer that starts in the tissue that forms blood.
The Relation of Negative Life Events to Symptoms and Functioning in Adolescents and Young Adults with a Childhood History of Chronic Abdominal Pain Presentation.
Characterization of Self-reported Asthma in Morbidly Obese Women Observational studies have shown obesity to be associated with increased risk of asthma.
Our Experiences With Natural Natural Products As Potential Therapeutic Agents : Towards Safer & Cost Effective Therapy Dr. Mrs.Chanda Kulkarni. MBBS; MD;
Optimization of Stem cell Therapy for degenerative Epithelial & Muscle Diseases March 2009 – February
Copyright © 2015 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 6 Clinical Use of the Electronic Health Record.
Exercise as a Recreational Therapy Treatment for Depression Tim Passmore, Ed.D., CTRS West Virginia Therapeutic Association Annual Conference Oklahoma.
1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.
Nutrition SUBJECTIVE FINDINGS  1 month prior to consult, patient claimed to have lost 20-30% of her weight (can be classified as severe weight loss),
CLAIMS STRUCTURE FOR SLE Jeffrey Siegel, M.D. Arthritis Advisory Committee September 29, 2003.
TAP PHARMACEUTICAL PRODUCTS INC. June 2, Arthritis Drugs Advisory Committee TAP Pharmaceutical Products Inc. June 2, 2004.
May Disclosures Philip L. McCarthy Jr. BMT Program Roswell Park Cancer Institute, Buffalo, NY –Participated in Dor Pharma acute Graft-versus-Host.
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin Belle L, Binsfeld M, Caers J, Dubois S, Briquet A, Hannon M, Beguin.
Adding a Biosocial Component to Understanding Society Research Methods Festival Session 56 – Understanding Society July 2010 Stephanie McFall.
1 Session 6 Minimally Important Differences Dave Cella Dennis Revicki Jeff Sloan David Feeny Ron Hays.
Ila Saunders, PharmD, BCOP Research Interests Impact of clinical pharmacy services in a matrix cancer center Impact of a “Transitions of Care” clinical.
Objective Measures of Physical Performance in Chronic GVHD: Adults Lynn H. Gerber, M.D. National Institutes of Health Bethesda, MD.
Determinants of Subjective Memory Complaints in Community-dwelling Adults with Traumatic Brain Injury Esther Bay, PhD; Bruno Giordani, PhD; Claire Kalpakjian,
Approaches for Estimating Minimally Important Differences Ron D. Hays, Ph.D. January 12, 2004 (8:50-9:10am) Minimal Clinically Important Differences in.
Pulmonary Rehabilitation in Asthma. Pulmonary Rehabilitation A well-established and widely accepted therapeutic tool that improves the quality of life.
Principles of Assessment and Outcome Measurement for Physical Therapists ksu. edu. sa Dr. taher _ yahoo. com Mohammed TA, Omar,
NUTRITIONAL ASSESSMENT :Clinical And Laboratory Aspects WORKSHOP 1 Merce Macalintal, MD 29 November 2009.
By: Ashlynn Hill. Patrice Thompson  3 year who is battling leukemia.  The doctors suggest a bone marrow transplants for a long term survival.  Neither.
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis.
Measurement Wu Gong, MS, MD
TREATMENT OF REFRACTORY CHRONIC GVHD WITH RITUXIMAB I. Vicuña (1), R
OA.
Overview of Chronic GVHD Response Assessment
Stephanie J. Lee, Loretta A. Williams 
A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus- Host Disease (cGVHD) Therapeutic Response Measures: Feasibility,
Seasonal Allergic Rhinitis
Charles D. Gerson, Mary-Joan Gerson 
Validation of National Institutes of Health Global Scoring System for Chronic Graft- Versus-Host Disease (GVHD) According to Overall and GVHD-Specific.
Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health.
A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus- Host Disease (cGVHD) Therapeutic Response Measures: Feasibility,
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis.
National Institutes of Health Chronic Graft-versus-Host Disease Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established.
Stephanie J. Lee, Loretta A. Williams 
Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study 
Validation of the Human Activity Profile Questionnaire in Patients after Allogeneic Hematopoietic Stem Cell Transplantation  Philipp Yorck Herzberg, Pia.
Outcomes in SCS Trials Ali Rezai MD.
Essentials of Good Pain Care: A Team-Based Approach
Measuring Therapeutic Response in Chronic Graft-versus-Host Disease
Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease  Saiko.
Diagnosing Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome
Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews  Emily C. Merkel, Sandra A. Mitchell,
The Research Question Lateral epicondylosis (tennis elbow) is common, debilitating and often refractory to routine care. Prolotherapy, an injection-based.
John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos 
Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after.
Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.
Oral Symptom Intensity, Health-Related Quality of Life, and Correlative Salivary Cytokines in Adult Survivors of Hematopoietic Stem Cell Transplantation.
William Berquist, MD  Gastrointestinal Endoscopy 
Presentation transcript:

Putting it All Together: Tools for Documenting Chronic GVHD Response Assessment Sandra A. Mitchell, CRNP, M.Sc.N., AOCN National Institutes of Health Bethesda, MD

Components of Chronic GVHD Response Evaluation Chronic GVHD-specific core measures –Clinician assessed –Self-report Chronic GVHD-non-specific ancillary measures –Clinician assessed –Self-report

Chronic GVHD-Specific Core Measures—Clinician Assessed –Skin –Eyes –Mouth –Gastrointestinal symptoms –Laboratory Studies –Pulmonary Function Tests –Health care provider global ratings of chronic GVHD severity (mild, moderate, severe), symptom severity (0–10 scale), and 7-point interval change score

Chronic GVHD-Specific Core Measures—Patient Self-Report Lee Chronic GVHD Symptom Scale

Chronic GVHD Non-Specific Ancillary Measures—Clinician Assessed –Weight –Functional Performance (2 minute walk and grip strength) –Karnofsky/Lansky Performance Status –Range of motion (attach physical therapy report

Chronic GVHD Non-Specific Ancillary Measures—Patient Self-Report –Self-report measures (adults): –Human Activity Profile –SF-36 –FACT-BMT –Self-report measures (children): –Activities Scale for Kids (ASK) –Child Health Ratings Inventories -Hematopoietic Stem Cell Transplant Module (CHRIs-HSCT).

Chronic GVHD Activity Assessment—Clinician Click here to open Appendix E: Response Criteria Evaluation form—Clinician

Chronic GVHD Activity Assessment—Clinician Click here to open Appendix E: Response Criteria Evaluation form—Clinician

Chronic GVHD-Specific Core Measures—Patient Reported Peak symptom severity in the last seven days, 0-10 scale: –Itching –Mouth dryness (subjective decrease in oral wetness) –Mouth pain (in the absence of stimulation such as swallowing or oral hygiene) –Mouth sensitivity (irritation resulting from normally tolerated spices, foods, liquids or flavors) –Main eye complaint Presence/absence of vulvovaginal symptoms (if present, refer for specialist examination)

Chronic GVHD-Specific Core Measures—Patient Reported Patient’s overall evaluation of: –Chronic GVHD severity (mild, moderate, severe) –Overall chronic GVHD symptom severity (0–10 scale) –Whether, compared to one month ago, their chronic GVHD symptoms are very much worse to very much better on a 7- point scale

Chronic GVHD Activity Assessment—Patient Self-Report Click here to open Appendix E: Response Criteria Evaluation Form—Patient

Proposed Measures (Forms A&B) MeasureClinician assessedPatient reported Core – Chronic GVHD Specific SignsOrgan specific measuresN/A Symptoms Clinician assessedPatient reported Lee Symptom Scale Global Rating7 point change scale 7 point change scale Mild-moderate-severeMild-moderate-severe 0-10 severity scale0-10 severity scale Ancillary - CGVHD Non-Specific FunctionGrip StrengthHAP 2 min walk timeASK (children) Performance statusKarnofsky/LanskyN/A Quality of lifeN/AFACT-BMT SF-36 v.2 CHRIs-HSCT (children)

Interval for Evaluation Intervals for re-evaluation are study protocol specific Suggest that measures are made at 3 month intervals and whenever a major change is made in treatment

For More Information More detailed information about the response criteria is available in the publication: “Measuring Therapeutic Response in Chronic Graft-Versus-Host Disease, NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: IV. Response Criteria Working Group Report” In: Biology of Blood and Marrow Transplantation, 2006 (in press). –Available at Supplementary information and updates are available at